TriangleZanubrutinib + Pola-R-CHP (NCT06730542)
Zanubrutinib + Pola-R-CHP trial for Secondary CNS Lymphoma (NCT06730542). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with lymphoma that has spread to the brain or spinal cord, called secondary CNS lymphoma.
The idea: add zanubrutinib, a capsule that blocks a protein called BTK, to standard treatment. That standard is Pola-R-CHP, a chemotherapy and antibody combination, plus high dose methotrexate, which can reach the brain.
The study looks at the good and bad effects of adding zanubrutinib.
This phase 1 study plans 20 patients. At the University of Miami, Juan Alderuccio leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.